Patient Selection Is Crucial for Treatment Decisions in Metastatic Melanoma After PD-1 Inhibition
Source: OncLive, May 2025
Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.
Although FDA-approved therapies such as lifileucel (Amtagvi) offer additional treatment options for patients with metastatic melanoma who received prior PD-1 inhibition, clinicians must consider a variety of patient-specific factors when deciding on the appropriate treatment for an individual patient, according to Stergios Moschos, MD.
In February 2024, lifileucel was granted accelerated approval by the FDA for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. The regulatory decision was supported by data from the phase 2 C-144-01 trial (NCT02360579), which demonstrated that patients who received the recommended dose of lifileucel (n = 73) achieved an objective response rate (ORR) of 31.5% (95% CI, 21.1%-43.4%); the median duration of response (DOR) was not yet reached (NR; 95% CI, 4.1 months-NR).